After receiving marketing authorization from the European Commission in September 2021, after 17 years of research and development, the company last month made its “new generation” of pasteurized healthy bacteria available in Belgium, the Netherlands. -Bas and Luxembourg.
And then the company revealed that the product will be distributed in Italy from mid-December through the pharmacy and parapharmacy channel, all exclusively through Metagenics Europe.
Positioned for weight management with glycemic control, the product contains the pasteurized bacteria Akkermansia muciniphila, which is recognized as a Novel Food by EFSA.
In addition to the 30 billion pasteurized Akkermansia muciniphila, it also contains chromium for blood sugar control and green tea extract for weight control, ingredients that allow it to use EFSA claims.
Pasteurized Akkermansia muciniphila was developed The Akkermansia Company, then known as A-Mansia, a spin-off from the universities of Wageningen (Netherlands) and UCLouvain (Belgium).
The bacterium was isolated in 2004 from human intestinal microbiota and characterized in the laboratory of Professor Willem M. de Vos (Wageningen University), co-founder of The Akkermansia Company. Subsequently, the team of Professor Patrice D. Cani (UCLouvain), the other co-founder of the company, discovered the effects.
This bacterium is the guardian of the intestinal barrier, with many activities it performs. The lack of this commensal bacterium is linked to multiple diseases, such as obesity, diabetes, fatty liver disease and inflammation, and several other clinical studies are underway to investigate other possible impacts.
Producing and selling it as a living probiotic was practically impossible. But thanks to the pasteurization process, the researchers managed to “release” the signal molecules of Akkermansia, thus ensuring the same effectiveness as the living probiotic. The pasteurized form is more stable, has a long shelf life and is easy to administer.
The Akkermansia company is produced in Italy by Sacco System. And thanks to the high technological level of the Italian company, it was possible to find innovative solutions for the cultivation of the bacteria and the industrial production of the ingredient. A real revolution in the supplement sector.
Speaking about the partnership agreement with Metagenics, Michael Oredsson, CEO of The Akkermansia Company, said: “This distribution agreement is the first of a long series. It will generate revenue that will be reinvested in R&D, as well as in the creation of new jobs.”
Stijn Oste, CEO of Metagenics Europe, added: “We are very proud to be the first company to sign a partnership agreement with The Akkermansia Company. We plan to invest in research by promoting and carrying out clinical intervention studies in close collaboration with health specialists and research institutions. Products formulated with Akkermansia muciniphila pave the way for a new generation of dietary supplements.”